WO2000039294A1 - Porcine cells incapable of expressing cd40 antigen, for xenotransplantation - Google Patents
Porcine cells incapable of expressing cd40 antigen, for xenotransplantation Download PDFInfo
- Publication number
- WO2000039294A1 WO2000039294A1 PCT/EP1999/010332 EP9910332W WO0039294A1 WO 2000039294 A1 WO2000039294 A1 WO 2000039294A1 EP 9910332 W EP9910332 W EP 9910332W WO 0039294 A1 WO0039294 A1 WO 0039294A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- cells
- pig
- cell
- gene
- Prior art date
Links
- 238000002689 xenotransplantation Methods 0.000 title description 4
- 239000000427 antigen Substances 0.000 title description 2
- 108091007433 antigens Proteins 0.000 title description 2
- 102000036639 antigens Human genes 0.000 title description 2
- 108010063916 CD40 Antigens Proteins 0.000 claims abstract description 50
- 210000000056 organ Anatomy 0.000 claims abstract description 19
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 116
- 101150013553 CD40 gene Proteins 0.000 claims description 56
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 108020004414 DNA Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 24
- 108700028369 Alleles Proteins 0.000 claims description 21
- 241000282414 Homo sapiens Species 0.000 claims description 20
- 210000001161 mammalian embryo Anatomy 0.000 claims description 19
- 238000002744 homologous recombination Methods 0.000 claims description 18
- 230000006801 homologous recombination Effects 0.000 claims description 18
- 230000002950 deficient Effects 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 16
- 238000003780 insertion Methods 0.000 claims description 15
- 230000037431 insertion Effects 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 241000282898 Sus scrofa Species 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 206010052779 Transplant rejections Diseases 0.000 claims description 7
- 230000000415 inactivating effect Effects 0.000 claims description 7
- 238000012239 gene modification Methods 0.000 claims description 6
- 230000005017 genetic modification Effects 0.000 claims description 6
- 235000013617 genetically modified food Nutrition 0.000 claims description 6
- 108020005544 Antisense RNA Proteins 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 238000009395 breeding Methods 0.000 claims description 4
- 230000001488 breeding effect Effects 0.000 claims description 4
- 230000000394 mitotic effect Effects 0.000 claims description 4
- 108700019146 Transgenes Proteins 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108010009575 CD55 Antigens Proteins 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 238000010363 gene targeting Methods 0.000 description 15
- 210000002257 embryonic structure Anatomy 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 210000000287 oocyte Anatomy 0.000 description 10
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 241000282887 Suidae Species 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 238000000520 microinjection Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 210000000472 morula Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000015689 E-Selectin Human genes 0.000 description 3
- 108010024212 E-Selectin Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000012173 estrus Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 210000004340 zona pellucida Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 2
- 206010016825 Flushing Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101100099886 Sus scrofa CD40 gene Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 2
- 229960004409 cloprostenol Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical class CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 description 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960004509 serum gonadotrophin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
Definitions
- the present invention relates to biologically compatible material for use in transplants and to the production and use of such material.
- Organ transplantation has undergone significant development with modern immunosuppressants and the demand for organ transplantation has increased rapidly.
- Conventional transplantation surgery involves the transplantation from one animal of a particular species (generally human) to another of the same species. Such transplantations are termed allografts. Because of the current shortage of human donors for transplantable allografts, attention has focused on the possibility of using xenografts (transplants between species) in transplantation.
- T cell activation requires both engagement of the TCR by peptide/MHC and costimulation via one or more accessory molecules.
- a number of porcine accessory molecules have been shown to be compatible with their human ligands including CD86, CD58 (LFA-3), and CD54 (ICAM-1). Therefore, it is likely that human T cells are capable of mounting a direct response to a pig xenograft.
- CD40 is central to T cell activation, through the regulation of the expression of accessory molecules. Ligation of CD40 leads to up- regulation of accessory molecules in a number of cell types including B cells, endothelial cells and dendritic cells. There is also evidence to suggest that cross linking of CD154 to the CD40 receptor provides a direct stimulus to the T cell. This may be a critical step in the initiation of cell mediated responses.
- Blocking antibodies to CD154 have been shown to prolong cardiac and pancreatic islet allografts in mice. Simultaneous blockade of both CD40 and CD28 pathways has been shown to further enhance cardiac and skin allograft survival in the mouse, and renal allograft survival in primates. Furthermore, this approach can greatly enhance survival of rat and pig skin grafts in mice.
- a method of preventing or inhibiting cellular graft rejection in a recipient mammal receiving a xenograft comprising using CD40-deficient donor mammal cells, tissues or organs as xenograft.
- a method of preventing or inhibiting cellular graft rejection in a recipient mammal receiving a xenograft comprising isolating cells, tissues or organs to be transplanted from a CD40-deficient donor mammal and transplanting said CD40-deficient cells, tissues or organs into the recipient mammal.
- the donor mammal may be a mouse, monkey, ape, pig, goat or cow, preferably a pig. According to a further aspect of the invention, there is provided:
- Graftable mammal preferably porcine, cells, tissues or organs, particularly such comprising CD40-deficient porcine EC, which are genetically modified to render them incapable of expressing CD40 antigen.
- the genetic modification may be an inactivation of the gene encoding CD40 antigen or an insertion of antisense RNA interfering with CD40 antigen expression.
- the genetically modified cells, tissues or organs are useful e.g. in preventing in humans symptoms associated with organ or tissue xenograft transplant rejection, e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic (complete or partial, e.g. Langerhans islets), skin, corneal transplants or bone marrow, particularly transplant vasculopathies.
- organ or tissue xenograft transplant rejection e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic (complete or partial, e.g. Langerhans islets), skin, corneal transplants or bone marrow, particularly transplant vasculopathies.
- a method of transplanting CD40-deficient porcine cells, tissues or organs into a recipient comprising grafting the CD40-deficient porcine cells, tissues or organs in the recipient.
- the pig CD40-deficient cells, tissues or organs comprise CD40-deficient EC.
- the present invention also comprises the porcine nucleic acid sequence that encodes a porcine polypeptide having CD40 antigen activity. Variations on this sequence that may be routinely generated by the skilled person include those varying within the scope of the degeneracy of the genetic code.
- the present invention also includes a porcine nucleic acid sequence that encodes porcine CD40 antigen and that hybridizes under standard high stringency conditions with a sequence complementary within the scope of the degeneracy of the genetic code. The complementary strands to above nucleic acid sequences are determined by standard methods and are also within the scope of the invention.
- the present invention also comprises a host cell transformed with any of above mentioned nucleic acid molecules, as well as porcine CD40 antigen encoded by such transforming nucleic acid molecules and expressed from the host cell.
- Methods for transforming appropriate host cells and for expressing polypeptides from such host cells are known in the art and are described, for example, in Sambrook et al., (1984), 12.2-12.44; 16.3-17.44.
- the invention further comprises a DNA construct useful for inactivating the gene encoding porcine CD40 antigen by insertion of a desired DNA sequence into an insertion site of said gene.
- Said gene includes the exons encoding or potentially encoding CD40antigen, introns contigous with such exons and regulatory elements associated with such exons and introns.
- the DNA construct includes the desired DNA sequence flanked by first and second homology sequences. These first and second homology sequences are sufficiently homologous, respectively, to first and second genomic sequences flanking the insertion site to allow for homologous recombination of the DNA construct with the porcine gene encoding CD40 antigen when the DNA construct is introduced into a target cell containing the porcine CD40 antigen gene.
- a replacement-type DNA construct containing part of the genomic CD40 antigen gene sequence with a mutant foreign sequence such as a positive selection marker inserted within the coding region may also be used instead of an insertion construct for inactivating the gene encoding the CD40 antigen.
- the construct is linearized outside the region of homology. Such a construct recombines with the CD40 antigen gene by a double crossover event, resulting in the replacement of the chromosomal DNA.
- the gene is preferably interrupted within an appropriate coding exon by insertion of an additional DNA fragment, preferably a gene coding for a selectable marker. Specific exons may be identified as preferred locations for disruption of the gene by homologous recombination.
- the regulatory elements associated with the coding sequence may also present useful targets for inactivation.
- a Sail site may be engineered into the corresponding location of the pig sequence for convenient construction of a knock-out sequence.
- the presence of a Sail site in the exon is useful since it is not likely that other Sail sites will be present at other locations in the knock-out constructs.
- the selectable marker is flanked by sequences homologous to the sequences flanking the desired insertion site. Any selective marker suitable for inclusion in a knock-out vector may be used.
- the gene imparting resistance to the antibiotic G418 (neomycin derivative) frequently is used although other antibiotic resistance markers (e.g. hygromycin) also may be employed.
- Other selection systems include negative selection markers, e.g. the thymidine kinase gene from Herpes simplex.
- the invention also includes methods for generating a pig totipotent cell having at least one inactivated (non-functional) CD40 antigen allele.
- totipotent cells is understood pluripotent cells (cells capable of giving rise to at least several differentiated cell types) capable of giving rise to all cell types of an embryo, including germ cells.
- the totipotent cells can include without limitation embryonic stem (ES) cells, e.g. blastocysts, primordial germ cells (PG) and eggs.
- ES embryonic stem
- PG primordial germ cells
- a "functional" allele is capable of being transcribed and translated to produce a polypeptide having an activity the same as or substantially similar to the native CD40 antigen.
- the methods include providing a plurality of cells characterized as pig totipotent cells, introducing into the totipotent cells a nucleic acid construct effective for inactivating the CD40 antigen gene by insertion of a desired DNA sequence into an insertion site of the gene through homologous recombination, and then identifying a totipotent cell having at least one inactivated CD40 antigen allele.
- transformation is defined as introduction of exogenous DNA into the target cell by any means known, e.g. transfection, microinjection, infection (e.g. with a retroviral vector), electroporation and microballistics.
- transfection e.g. transfection, microinjection, infection (e.g. with a retroviral vector), electroporation and microballistics.
- homozygous cells can be generated by performing a second homologous recombination procedure on cells heterozygous for the CD40 antigen inactivated allele. If the knock-out construct used in the initial transformation carries one specific selectable marker, a second construct may be employed in a second round of transformation in which the selectable marker is replaced with a different selectable marker. Cells resistant to both selectable markers can be screened by Southern blots in order to detect any "double knock-outs" (i.e. homozygotes).
- the invention further includes methods for generating a pig lacking a gene encoding functional CD40 antigen, preferably a transgenic pig with CD40-deficient EC.
- the methods include providing a pig totipotent cell having at least one inactivated CD40 antigen allele, manipulating the totipotent cell such that mitotic descendants of the cell constitute all or part of a developing embryo, allowing the embryo to develop to term, recovering a neonate individual derived from the embryo and raising and breeding the neonate to obtain a pig homozygous for an inactivated CD40 antigen allele, i.e. in which both CD40 antigen alleles are inactivated.
- ES and PG cells are manipulated in various ways such that their mitotic descendants are found in a developing embryo, these manipulations can include, without limitation, injection into a blastocyst or morula, co-culture with a zona pellucida-disrupted morula, and fusion with an enucleated zygote.
- Cells injected into a blastocyst- or morula-stage embryo become incorporated into the inner cell mass of the blastocyst embryo, giving rise to various differentiated cell types of the resulting embryo, including in some cases germ cells.
- the embryo derived from such manipulations is a chimera composed of normal embryonic ES or PG cells.
- chimeric embryos can be obtained by co-culturing at least one ES or PC cell with a morula embryo in which the zona pellucida is sufficiently disrupted to allow direct contact between ES cell/PC cell and at least one cell of the morula.
- the zona pellucida-disrupted embryo may be an embryo that is completely free of the zona pellucida.
- the genome of an ES or PG cell can be incorporated into an embryo by fusing the ES cell/PG cell with an enucleated zygote.
- Such a procedure is capable of generating a non-chimeric embryo, i.e. an embryo in which all nuclei are mitotic descendants of the fused ES cell/PG cell nucleus.
- the resulting embryos are implanted in a recipient female or surrogate mother, allowed to develop to term, raised to sexual maturity and bred to obtain pigs carrying the inactivated CD40 antigen allele. If the original ES cell was heterozygous for the inactivated CD40 antigen allele, several of these animals will be bred with each other to generate animals homozygous for the inactivated CD40 antigen gene.
- eggs When eggs, as opposed to ES or PG cells, are directly injected with a nucleic acid construct effective for inactivating the CD40 antigen gene, the eggs can be manipulated to form and embryo by implanting into a recipient female.
- the direct injection of eggs can be a useful approach since it avoids the special manipulations required to turn a cultured cell into an animal.
- Fertilized eggs are "totipotent" , i.e. capable of developing into an adult without further substantive manipulation other than implantation into a surrogate mother. It may be useful to prepare the knock-out constructs from isogenic DNA, e.g. the constructs may be prepared from DNA isolated from the boar whose sperm is employed to fertilize the eggs used for injection.
- Embryos derived from microinjected eggs can be screened for homologous recombination events in several ways, e.g. using the detection properties of the detectable marker inserted in the CD40 antigen gene.
- the piglets may be analyzed by polymerase chain reaction (PCR) or reverse transcription PCR for evidence of homologous recombination.
- Transgenic CD40-deficient pig tissue or cells may also be prepared by causing the expression of antisense RNA molecules interfering with the expression of CD40 antigen, particularly in EC.
- Exogenous nucleic acid molecules designed to specifically inhibit the expression of the native CD40 antigen within a pig cell may be used. These genetic manipulations include the use of nucleic acid molecules specially engineered to allow gene inactivation using antisense RNAs techniques.
- Antisense RNAs can be used to specifically inhibit gene expression (see for example Eguchi et al, Annu. Rev. Biochem. 60, 631-652, 1991). Such RNA molecules can be expressed by recombinant nucleic acid molecules engineered accordingly for expression in the pig cells. v
- transgenic pig having transplantable CD40-deficient tissue or cells, preferably such comprising EC.
- CD40 antigen mRNA should be absent from homozygous knock-out pigs. This can be confirmed e.g. with RT PCR.
- Anti-CD40 antibodies can also be used in various assay to test for the presence of the CD40 epitope in an array of tissues. 1.Cloning porcine CD40 cDNA
- a porcine spleen cDNA library was constructed. mRNA from porcine spleen was isolated and reverse transcribed using Timesaver cDNA synthesis kit (Pharmacia). Using ZAP Express Pre-digested Vector Kit and ZAP Express Pre-digested Gigopack III Gold Cloning Kit (Stratagene), a phagemid cDNA library was constructed. The library contained approximately 1.4 x 10 6 representative clones, these were amplified 100-fold. Approximately 10 6 pf u's of the amplified library were screened for pCD40 cDNA.
- COS cells were plated at 50% confluency in six well tissue culture plates. Cells were washed in phosphate buffered saline (Gibco) before transfection and 3hrs post transfection, followed by incubation in DMEM (Gibco), 10% fetal calf serum, 2mM L- Glutamine, 200U/ml penicillin and 200ug/ml streptomycin. Transfected cells were analysed 48hrs post-transfection for cell surface expression of pCD40 and hCD40 molecules.
- Jurkat E6.1 , L-23 and L-52 cells were all obtained from the European collection of animal cell cultures (CAMR, Porton Down, UK).
- Jurkat cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2mM L-Glutamine, 200U/ml penicillin and 200 ⁇ g/ml Streptomycin (Sigma, Poole, UK).
- L-23 and L-24 cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated foetal calf serum, 2mM L-Glutamine, 200U/ml penicillin, 200 ⁇ g/ml Streptomycin, 1mM Sodium Pyruvate (Sigma), and 20 ⁇ M 2-mercaptoethanol (BDH).
- PBMC Human buffy coat was obtained from the Blood Transfusion Service, Cambridge, and heparinised pig blood was obtained from normal pigs from our own breeding colony.
- PBMC were prepared from both human and pig blood by density gradient centrifugation using Hypaque (Sigma).
- a fusion protein consisting of the extracellular domain of human CD154 coupled to mouse Ig K light chain was employed. This fusion protein is known to be biologically active in a B cell activation assay.
- the Jurkat cells do not bind human CD154-lg, whereas both pig B cell lines showed a high level of binding.
- CD40 blockade has been demonstrated to be efficacious in a number of models, it remained undemonstrated whether direct signalling through the CD40 pathway is possible between porcine and human cells.
- the inventors have demonstrated the ability of human CD154 (hCD154) to bind pCD40 which indicates that direct signalling between a porcine graft and the immune cells of a human host is possible through this molecular pathway. From this it is reasonable to infer that CD40 signalling contributes to cellular activation during xenograft rejection and that, the inhibition or ablation of this signal could extend xenograft survival.
- CD40 pathway may be involved in activation of vascular endothelium in porcine xenografts.
- CD40 activation of pig aortic EC leads to up-regulation of MHC class. Since a number of cells can express CD154 including T cells, NK cells and platelets, it is possible these may contribute to EC activation. Therapies that target CD40/CD154 interactions or the signalling pathways involved reduce EC activation, and therefore improve xenograft survival.
- the frequency of homologous recombination in embryos is improved if the gene targeting constructs are prepared with isogenic DNA. Therefore the "knock out" constructs are prepared from DNA isolated from the boar used to fertilize the oocytes used for microinjection. DNA is isolated from the tail or ear tissue, and genomic fragments from both CD40 antigen alleles of the boar encompassing the coding region are cloned using long range PCR or conventional genomic library technologies. Clones for each of the CD40 antigen alleles are identified using restriction fragment length polymorphism identification and DNA sequencing. Constructs to target both alleles are made by interrupting the coding sequence either by deletion or by inserting a heterologous DNA fragment.
- the constructs contain at least 8 kb of homologous DNA to promote efficient homologous recombination.
- Various approaches can be used to detect gene targeting events, depending on the strategies used in designing the knockout constructs.
- Several such approaches, and the corresponding strategies for construction of constructs may be used as follows: i) PCR of Genomic DNA: Homologous DNA on one side of the interrupting DNA fragment is constructed to be less than 1 kb, allowing PCR amplification of a short diagnostic fragment. (Amplification of small fragments generally is relatively efficient).
- ii) Reverse Transcription PCR A deletion of about 100 bp within the coding region is made, allowing synthesis of a shortened CD40 antigen mRNA in correctly targeted cells. The shortened mRNA is detected by RT PCR, using primers that amplify a fragment encompassing the deletion site.
- the protocol involves: i)sperm from the boar providing DNA for the targeting construct is collected and stored frozen in liquid N 2 . ii) Superovulation of donor gilts:
- Gilts are mated at the second oestrus, and aborted between days 25-40 days of gestation to synchronise the subsequent oestrus cycles. Abortion is achieved by intramuscular injection of 1 mg cloprostenol (a prostaglandin F2 ⁇ analogue), followed by a second 0.5 mg injection 24 hours later. Gilts are superovulated by injection of 1000 i.u. equine chorionic gonadotrophin (eCG) or pregnant mare serum gonadotrophin at the time of the second cloprostenol injection, and a subsequent injection 72 hours later of 500 i.u. human chorionic gonadotrophin (hCG).
- eCG equine chorionic gonadotrophin
- hCG human chorionic gonadotrophin
- Embryos are collected surgically 50-56 hours after hCG injection prior to fusion of the pronuclei. Oviducts are flushed with 15-20 ml phosphate saline buffer containing 1 % fetal calf serum. One-cell embryos are recovered by searching oviductal flushings using low magnification microscopy.
- Embryos are centrifuged at 12000 x g for 8 min to stratify the cytoplasm and allow the pronuclei to be visualised, and held in Dulbecco's Minimal Essential Medium with 25 mM Hepes and 5 mg/ml bovine serum albumin. Pronuclei are injected, using differential interference contrast optics, with 4-10 picolitres of DNA (10 ng/ ⁇ l) in PBS. Gene targeting with isogenic DNA is maximized by coinjecting both allelic constructs derived from the boar into the male pronucleus. d. Transfer of injected embryos to recipient gilts
- the oestrus cycles of recipient gilts are synchronized with those of donors.
- the recipients are mated and aborted using the protocol described above, and injected with 500 i.u. eCG.
- Injected embryos are transferred surgically (20-40 per oviduct) to recipients on the same day that they are collected from donor gilts:
- Homologous recombinants can be detected by analysis of tissue from the born piglets. Screening procedures involve PCR technology, the precise strategy depending on the design of the gene targeting construct. The RT PCR approach can be more sensitive than PCR amplification of genomic DNA. The RT PCR screening strategy relies on successful transcription of the interrupted gene and relative stability of the shortened mRNA.
- the chromosomal CD40 gene in pig cells is mutated by homologous recombination with a gene targeting vector.
- the gene targeting vector comprises sections of DNA that are homologous to regions within or adjacent to the chromosomal CD40 gene. Ideally, these homologous sequences are identical in sequence over as large a region as is practicable.
- total genomic DNA is purified from porcine cells or tissues.
- the porcine genomic DNA is used to construct a library by conventional techniques.
- the porcine genomic library is screened using the cDNA, either whole or fragments thereof, for porcine CD40.
- the DNA sequence of the porcine CD40 cDNA is provided herein.
- genomic sequences are verified using restriction enzyme mapping or DNA sequencing.
- DNA homologous to regions within or adjacent to the porcine CD40 gene is combined, using standard DNA manipulation techniques, with sequences which may be genes or parts of genes that facilitate, through selection or screening, the identification of cells containing the products of a gene targeting event.
- Gene targeting may also be performed using small oligonucleotides with DNA sequence homologous to the CD40 locus and derived from the porcine CD40 cDNA or porcine CD40 genomic DNA.
- gene targeting vectors are designed to delete or inactivate the chromosomal CD40 gene.
- a CD40 gene targeting vector is used to mutate one or both alleles of the chromosomal CD40 gene in porcine cells.
- the CD40 gene targeting vector is introduced into porcine cells that are in culture in the laboratory using any of a range of DNA transfection techniques that are standard practise. These techniques include, but are not limited to, Calcium Phosphate transformation, electroporation, lipofection and micro-injection. Homologous recombination is a low frequency event and a variety of strategies may be used to identify porcine cells in which a CD40 locus has been modified in the desired way.
- the cells used may be any porcine cell type or cell line that grows sufficiently well in culture to enable the homologous recombination event to be performed.
- the cells include porcine embryonic cells, porcine somatic cells grown from tissue obtained from a adult pig or a developing foetus or embryo, porcine primordial germ cells, porcine embryonic germ cells and porcine foetal fibroblasts. Porcine cells containing a mutation at one or both CD40 alleles are expanded in culture using standard techniques.
- Porcine cells having the desired genetic modification of the CD40 gene are used as donors for nuclear transfer. Porcine cells are fused with enucleated porcine oocytes. A micro- manipulation needle is used to introduce the porcine cell of the desired genotype under the zona pellucida of the enucleated oocyte. Fusion of the introduced cell with the oocyte is induced, usually by an electric pulse. This results in a porcine oocyte that contains the nucleus and the genetic material, including the mutated CD40 gene, of the chosen donor cell. The porcine oocyte containing the mutated CD40 gene is cultured for a period typically, but not necessarily, of four and a half hours before the oocyte is activated.
- Activation may be achieved chemically, for example using ionomycin.
- Alternative methods may be used to activate the oocyte.
- the oocyte may then be implanted, immediately or following culture and further manipulation, in to the uterus of a sow.
- Implanted oocytes may develop to term to produce neonatal pigs that have the specific CD40 mutation that was engineered in to the cultured porcine cells.
- neonates may have the CD40 mutation at one or both alleles.
- the presence of the CD40 mutation in pigs may be demonstrated using any of a range of standard molecular techniques including, but not limited to, Southern analysis, PCR, DNA sequencing, or RFLP analyses.
- pigs may be obtained which are heterozygous or homozygous for the CD40 mutation. These pigs may therefore be CD40 deficient. Standard breeding may also be used to generate pigs that carry the CD40 mutation in addition to further genetic modifications. These further genetic modifications include transgenes or other mutations generated by gene targeting or homologous recombination.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU21016/00A AU2101600A (en) | 1998-12-24 | 1999-12-22 | Porcine cells incapable of expressing cd40 antigen, for xenotransplantation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9828705.5A GB9828705D0 (en) | 1998-12-24 | 1998-12-24 | Organic compounds |
GB9828705.5 | 1998-12-24 | ||
GB9902940.7 | 1999-02-10 | ||
GBGB9902940.7A GB9902940D0 (en) | 1999-02-10 | 1999-02-10 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000039294A1 true WO2000039294A1 (en) | 2000-07-06 |
Family
ID=26314930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/010332 WO2000039294A1 (en) | 1998-12-24 | 1999-12-22 | Porcine cells incapable of expressing cd40 antigen, for xenotransplantation |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2101600A (en) |
WO (1) | WO2000039294A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000051630A2 (en) * | 1999-03-05 | 2000-09-08 | Diacrin, Inc. | Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent |
WO2004078022A3 (en) * | 2003-03-06 | 2007-11-29 | Yeda Res & Dev | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
US7780993B2 (en) | 2001-09-07 | 2010-08-24 | Yeda Research And Development Co. Ltd. | Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts |
WO2012032526A2 (en) | 2010-09-08 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment |
WO2013013708A1 (en) * | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
WO2013035099A1 (en) | 2011-09-08 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
US8974779B2 (en) | 2003-03-06 | 2015-03-10 | Yeda Research And Development Co. Ltd. | Disease treatment via developing non-syngeneic graft transplantation |
WO2017009852A1 (en) | 2015-07-16 | 2017-01-19 | Yeda Research And Development Co. Ltd. | Use of anti third party central memory t cells |
WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
WO2018002924A1 (en) | 2016-06-27 | 2018-01-04 | Yeda Research And Development Co. Ltd. | Veto cells generated from memory t cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034633A1 (en) * | 1996-03-20 | 1997-09-25 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
-
1999
- 1999-12-22 WO PCT/EP1999/010332 patent/WO2000039294A1/en active Application Filing
- 1999-12-22 AU AU21016/00A patent/AU2101600A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034633A1 (en) * | 1996-03-20 | 1997-09-25 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
Non-Patent Citations (5)
Title |
---|
ELWOOD ET ET AL: "Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade", TRANSPLANTATION, vol. 65, no. 11, 15 June 1998 (1998-06-15), pages 1422 - 1428, XP000906866 * |
Meeting paper Conference on Xenotransplantation: Scientific Frontiers and public Policy New York USA March 18-20, 1998 * |
Meeting paper from XVIIth World Congress of the Transplantation Society; Montreal, Quebec, Canada; July 12-17, 1998 * |
VANHOVE B ET AL: "Genetic Engineering in the pig. Gene knockout and alternative techniques", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 862, 30 December 1998 (1998-12-30), pages 28 - 36, XP000906935 * |
WEST KA ET AL: "Cloning of the porcine costimulatory molecule CD40", TRANSPLANTATION PROCEEDINGS, vol. 31, no. 1/2, February 1999 (1999-02-01) - March 1999 (1999-03-01), pages 928 - 929, XP000906928 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000051630A3 (en) * | 1999-03-05 | 2001-01-18 | Diacrin Inc | Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent |
WO2000051630A2 (en) * | 1999-03-05 | 2000-09-08 | Diacrin, Inc. | Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent |
US7780993B2 (en) | 2001-09-07 | 2010-08-24 | Yeda Research And Development Co. Ltd. | Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts |
US8951572B2 (en) | 2001-09-07 | 2015-02-10 | Yeda Research And Development Co. Ltd. | Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts |
US8974779B2 (en) | 2003-03-06 | 2015-03-10 | Yeda Research And Development Co. Ltd. | Disease treatment via developing non-syngeneic graft transplantation |
AU2004217938B2 (en) * | 2003-03-06 | 2009-06-11 | Yeda Research And Development Co. Ltd | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
WO2004078022A3 (en) * | 2003-03-06 | 2007-11-29 | Yeda Res & Dev | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
WO2012032526A2 (en) | 2010-09-08 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment |
WO2013013708A1 (en) * | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
WO2013035099A1 (en) | 2011-09-08 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
WO2017009852A1 (en) | 2015-07-16 | 2017-01-19 | Yeda Research And Development Co. Ltd. | Use of anti third party central memory t cells |
WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
WO2018002924A1 (en) | 2016-06-27 | 2018-01-04 | Yeda Research And Development Co. Ltd. | Veto cells generated from memory t cells |
Also Published As
Publication number | Publication date |
---|---|
AU2101600A (en) | 2000-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6413769B1 (en) | α(1,3) galactosyltransferase negative porcine cells | |
EP1071471B1 (en) | Methods and vectors for making transgenic rodents which ubiquitously express a heterologous gene | |
CA2181433C (en) | Materials and methods for management of hyperacute rejection in human xenotransplantation | |
US20060057719A1 (en) | Carbohydrate determinant selection system for homologous recombination | |
JP2000516463A (en) | Method for producing a mammal having specific genetic characteristics | |
WO1995020661A1 (en) | Materials and methods for management of hyperacute rejection in human xenotransplantation | |
JP2002537785A (en) | Genetic modification of somatic cells and their use | |
AU7744800A (en) | Compositions and methods for altering gene expression | |
WO2000039294A1 (en) | Porcine cells incapable of expressing cd40 antigen, for xenotransplantation | |
US20060015955A1 (en) | Alpha(1,3)Galactosyltransferase enzyme that assembles the Galalpha(1,3)Gal xenoantigen | |
White et al. | The control of hyperacute rejection by genetic engineering of the donor species | |
US10717991B2 (en) | Transgenic pig which simultaneously expresses HO-1 gene and TNFR1-Fc gene, and comprises knocked-out GGTA1 gene, and use thereof | |
KR101588474B1 (en) | Method for introducing foreign gene into early embryo of primate animal, and method for production of transgenic primate animal comprising the introduction method | |
JP5771240B2 (en) | Immunodeficient pig | |
CN114686438B (en) | Construction method and application of ACE2 humanized pig | |
AU711144B2 (en) | Materials and methods for management of hyperacute rejection in human xenotransplantation | |
AU766519B2 (en) | alpha(1,3)-galactosyltransferase negative swine | |
AU2004200177B2 (en) | Alpha(1,3)-Galactosyltransferase Negative Swine | |
Cuthbertson et al. | Transgenic Mice—A Gold Mine for Furthering Knowledge in Pathobiology | |
JPH11192036A (en) | Creation of transgenic animal | |
AU1850599A (en) | Alpha(1,3)-glactosyltransferase negative swine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |